Skip to main content
OpenTrials
Completed

NCT Number: NCT04423016

Transitional Cerebrovascular Reactivity in Very Preterm Infants

The transitional period, defined as the first 72 hours after preterm birth, is often characterized by a significant hemodynamic instability and may also be associated with an impairment of cerebral autoregulation, with relevant clinical implications. The moving correlation coefficient between cerebral oxygenation and heart rate, also defined as TOHRx, has been previously proposed as a marker of cerebrovascular reactivity and provides an indirect estimation of cerebral autoregulation in preterm infants.

This study aims to evaluate whether different antenatal, perinatal and postnatal factors may influence cerebrovascular reactivity in very preterm infants during the transitional period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–3 day

Sex eligibility

All sexes

Study type

Observational

Primary location

Sant'Orsola-Malpighi University Hospital

Bologna, Emilia-Romagna, 40138, Italy

About this study

The transitional period, defined as the first 72 hours after preterm birth, is often characterized by a significant hemodynamic instability and may also be associated with an impairment of cerebral autoregulation, with relevant clinical implications. The moving correlation coefficient between cerebral oxygenation and heart rate, also defined as TOHRx, has been previously proposed as a marker of cerebrovascular reactivity and provides an indirect estimation of cerebral autoregulation in preterm infants.

This prospective observational study aims to evaluate whether different antenatal, perinatal, and postnatal factors may influence cerebrovascular reactivity in very preterm infants during the transitional period.

Infants <32 weeks' gestation are enrolled within 12h from birth. A simultaneous monitoring of cerebral oxygenation (CrSO2) by near-infrared spectroscopy and of heart rate (HR) by pulse oximetry and electrical velocimetry is performed continuously over the first 72h.

The moving correlation coefficient between CrSO2 and HR is calculated using the ICM+ software (Cambridge Enterprise Ltd) using 5-min, 30-point epochs. Time periods with evidence of major artefacts, or with a missing data proportion >50% are excluded from this calculation. Positive TOHRx values will be interpreted as markers of impaired autoregulation.

A screening echocardiogram is routinely performed at the time of enrollment and repeated 6-12 hourly in the presence of a patent ductus arteriosus (PDA) or 12-24 hourly if there is no evidence of PDA. Based on echocardiographic features, the ductal status is classified as follows: no evidence of PDA, restrictive PDA (restrictive shunt pattern and left atrium to aortic root ratio [LA:Ao] ratio <1.5), hemodynamically significant PDA (pulsatile shunt pattern, LA:Ao ratio ≥1.5 or presence of reversed end-diastolic flow either in the descending aorta or in the anterior cerebral artery).

A concomitant cerebral ultrasound scan, aimed at evaluating brain parenchyma and the occurrence of prematurity-related complications, such as intraventricular hemorrhage, is also performed.

During the study period, the following antenatal and neonatal data are tracked down on a specific case report form: gestational age (GA); birth weight (BW); non-invasive blood pressure; antenatal steroids (complete course vs. incomplete course or not given); evidence of reversed end-diastolic flow at antenatal umbilical Doppler (uREDF) (present vs. absent); ventilatory status over the first 72 hours of life (mechanical ventilation, continuous positive airway pressure [CPAP], nasal cannulas or self-ventilating in air [SVIA]); surfactant administration; development of IVH over the first 72 hours of life; ongoing inotropes (dopamine, dobutamine or both).

The correlation between antenatal, perinatal, and postnatal clinical variables and TOHRx is going to be evaluated using generalized linear mixed models or generalized estimating equations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • gestational age <32 weeks' gestation

Exclusion criteria

  • major congenital malformations
  • congenital heart disease

Treatment and study plan

Near Infrared Spectroscopy monitoring

Device

Non-invasive continuous monitoring of cerebral oxygenation

Electrical velocimetry and pulse oximetry

Device

Non-invasive continuous monitoring of cerebral oxygenation

Primary outcomes

  1. Correlation between TOHRx and gestational age

    Time frame: 0-72 hours

    Correlation between TOHRx and gestational age

  2. Correlation between TOHRx and antenatal steroids administration

    Time frame: 0-72 hours

    Correlation between TOHRx and antenatal steroids administration (full course vs. incomplete course or not given)

  3. Correlation between TOHRx and antenatal Doppler status

    Time frame: 0-72 hours

    Correlation between TOHRx and antenatal Doppler status (normal or abnormal)

  4. Correlation between TOHRx and ductal status

    Time frame: 0-72 hours

    Correlation between TOHRx and ductal status (hemodynamically significant, restrictive or closed)

  5. Correlation between TOHRx and respiratory support

    Time frame: 0-72 hours

    Correlation between TOHRx and respiratory support modality (mechanical ventilation, CPAP, nasal cannulas or self-ventilating in air)

  6. Correlation between TOHRx and inotropes

    Time frame: 0-72 hours

    Correlation between TOHRx and inotropes administration (dopamine; dobutamine; dopamine and dobutamine)

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Clinical Determinants of Cerebrovascular Reactivity in Very Preterm Infants During the Transitional Period

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jun 9, 2020
Registry last updated
Jul 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.